tradingkey.logo
tradingkey.logo

Adagio Medical Holdings Inc

ADGM
1.198USD
-0.042-3.35%
Market hours ETQuotes delayed by 15 min
16.04MMarket Cap
LossP/E TTM

Adagio Medical Holdings Inc

1.198
-0.042-3.35%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Adagio Medical Holdings Inc

Currency: USD Updated: 2026-03-27

Key Insights

Adagio Medical Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 126 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.00.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Adagio Medical Holdings Inc's Score

Industry at a Glance

Industry Ranking
126 / 208
Overall Ranking
299 / 4542
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Adagio Medical Holdings Inc Highlights

StrengthsRisks
Adagio Medical Holdings, Inc. is a commercial stage medical device company. It is focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia. It is developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for the treatment of ventricular arrhythmia.
Fairly Valued
The company’s latest PE is -0.81, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 14.35M shares, increasing 14.80% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 79.45K shares of this stock.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
4.000
Target Price
+222.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Adagio Medical Holdings Inc is 6.66, ranking 131 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score
6.66
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.47

Operational Efficiency

2.67

Growth Potential

6.14

Shareholder Returns

7.03

Adagio Medical Holdings Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Adagio Medical Holdings Inc is 5.59, ranking 182 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.81, which is -100.00% below the recent high of 0.00 and -659.49% above the recent low of -6.14.

Score

Industry at a Glance

Previous score
5.59
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 126/208
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Adagio Medical Holdings Inc is 8.00, ranking 61 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 4.00, with a high of 4.00 and a low of 4.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
4.000
Target Price
+222.58%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

92
Total
4
Median
7
Average
Company name
Ratings
Analysts
Adagio Medical Holdings Inc
ADGM
1
Boston Scientific Corp
BSX
36
Intuitive Surgical Inc
ISRG
36
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
19

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Adagio Medical Holdings Inc is 3.73, ranking 196 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 1.45 and the support level at 0.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
3.76
Change
-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(3)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.046
Buy
RSI(14)
67.147
Neutral
STOCH(KDJ)(9,3,3)
65.303
Neutral
ATR(14)
0.128
Low Volatility
CCI(14)
73.054
Neutral
Williams %R
29.337
Buy
TRIX(12,20)
0.734
Sell
StochRSI(14)
24.120
Sell
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
1.216
Sell
MA10
1.139
Buy
MA20
1.068
Buy
MA50
1.020
Buy
MA100
0.978
Buy
MA200
1.251
Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

Score

Industry at a Glance

Previous score
7.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Perceptive Advisors LLC
9.88M
+0.00%
Sio Capital Management, LLC
1.29M
--
Adage Capital Management, L.P.
1.06M
+28.89%
Adar1 Capital Management LLC
1.21M
--
Usen (Todd)
662.46K
+45.55%
Mizuho Securities USA, LLC.
208.79K
-13.67%
1
2

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Adagio Medical Holdings Inc is 1.46, ranking 189 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.01. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
1.46
Change
0
Beta vs S&P 500 index
-0.04
VaR
--
240-Day Maximum Drawdown
+67.37%
240-Day Volatility
+153.57%

Return

Best Daily Return
60 days
+16.13%
120 days
+41.95%
5 years
--
Worst Daily Return
60 days
-5.97%
120 days
-22.31%
5 years
--
Sharpe Ratio
60 days
+1.53
120 days
-0.39
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+67.37%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+0.88
3 years
-0.29
5 years
-0.18
Skewness
240 days
+4.42
3 years
+3.25
5 years
--

Volatility

Realised Volatility
240 days
+153.57%
5 years
--
Standardised True Range
240 days
+12.14%
5 years
+140.30%
Downside Risk-Adjusted Return
120 days
-65.72%
240 days
-65.72%
Maximum Daily Upside Volatility
60 days
+79.85%
Maximum Daily Downside Volatility
60 days
+56.48%

Liquidity

Average Turnover Rate
60 days
+0.29%
120 days
+8.10%
5 years
--
Turnover Deviation
20 days
-100.00%
60 days
-100.00%
120 days
-100.00%

Peer Comparison

Healthcare Equipment & Supplies
Adagio Medical Holdings Inc
Adagio Medical Holdings Inc
ADGM
5.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
Bioventus Inc
BVS
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI